An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...
In an interview with Targeted Oncology, David Zhen, MD, a medical oncologist and associate professor in the clinical research division at the Fred Hutchinson Cancer Center and associate professor in ...
The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback